Table 23.7Timeline of chemotherapy studies

Year5-FU basedPlatinum basedPlatinum/taxane based
1980Woods 1980 (doxorubicin, mitomycin-C)
Woods 1980 (5-fluorouracil, cyclophosphamide, methotrexate,)
1981Gisselbrecht 1981 (5-fluorouracil, doxorubicin, cisplatin)
1983Shildt 1983 (CI-5-fluorouracil)
Shildt 1983 (CI-5-fluorouracil, doxorubicin, cyclophosphamide)
1984Piot 1984 (CI-5-fluorouracil, doxorubicin, cisplatin)
1986Goldberg 1986 (5-fluorouracil, doxorubicin, mitomycin-C)
1988Sulkes 1988 (5-fluorouracil, doxorubicin, mitomycin-C)
Sulkes 1988 (doxorubicin, vinblastine, mitomycin-C)
Van der Gaast 1988 (5-fluorouracil, doxorubicin, mitomycin-C)
1989Treat 1989 (methotrexate, 5-fluorouracil, doxorubicin, mitomycin-C)
1990Al Idrissi 1990 (5-fluorouracil, doxorubicin, mitomycin-C)
Kambu 1990 (doxorubicin, vindesine, mitomycin-C)
Romero 1990 (etoposide, mitomycin-C)
1991Gill 1991 (cisplatin, etoposide)
Raber 1991 (cisplatin, etoposide, CI-5-fluorouracil)
Wagener 1991 (cisplatin)
1992Kelsen 1992 (5-fluorouracil, methotrexate, leucovorin, N-phosphonacetyl-L-aspartate)Hainsworth 1992 (cisplatin based)
Pavlidis 1992 (cisplatin or carboplatin based)
1993Nole 1993 (5-fluorouracil, folinic acid)
1995Khansur 1995 (cisplatin, CI-5-fluorouracil)
1996Farrugia 1996 (platinum based (including 5-FU in most cases))
1997Rigg 1997 (carboplatin, leucovorin, 5-fluorouracil)
1998Briasoulis 1998 (carboplatin, epirubicin, etoposide)
Falkson 1998 (cisplatin, mitomycin-C, epirubicin)
Warner 1998 (carboplatin, etoposide)
1999Culine 1999 (carboplatin, etoposide, doxorubicin, cyclophosphamide)
Lofts 1999 (cisplatin, CI-5-fluorouracil, tamoxifen)
2000Parnis 2000 (cisplatin, epirubicin, CI-5-fluorouracil)Briasoulis 2000 (paclitaxel, carboplatin)
Raats 2000 (cisplatin, ralitrexed)Greco 2000 (docetaxel, cisplatin)
Voog 2000 (cisplatin, etoposide)Greco 2000 (docetaxel, carboplatin)
Greco 2000a (paclitaxel, carboplatin, etoposide)
2001Guardiola 2001 (cisplatin, doxorubicin, cyclophosphamide)Darby 2001 (docetaxel)
Karapetis 2001 (cyclophosphamide, etoposide, CI-5-fluorouracil)Dowell 2001 (paclitaxel, 5-fluorouracil, leucovorin)
Sagatchian 2001 (platinum based)
2002Culine 2002 (doxorubicin, cyclophosphamide, cisplatin, etoposide)
Macdonald 2002 (cisplatin, mitomycin-C, CI-5-fluorouracil)
2003Balana 2003 (cisplatin, gemcitabine, etoposide)Mukai 2003 (docetaxel, cisplatin)
Culine 2003 (cisplatin, gemcitabine)
Culine 2003 (cisplatin, irinotecan)
2004Piga 2004 (carboplatin, etoposide, doxorubicin)Greco 2004 (paclitaxel, carboplatin, etoposide -- gemcitabine, irinotecan)
Munoz 2004 (paclitaxel, carboplatin, etoposide)
Park 2004 (paclitaxel, cisplatin)
Pouessel 2004 (docetaxel, gemcitabine)
2005El Rayes 2005 (paclitaxel, carboplatin)
Van de Wouw 2005 (paclitaxel, carboplatin, etoposide)
2006Palmeri 2006 (cisplatin, gemcitabine, vinorelbine)Hainsworth 2006 (paclitaxel, carboplatin, etoposide)
Pittman 2006 (carboplatin, gemcitabine)Mel 2006 (docetaxel, carboplatin, gemcitabine)
Palmeri 2006 (paclitaxel, cisplatin, gemcitabine)
2007Briasoulis 2007 (oxaliplatin, irinotecan)Berry 2007 (paclitaxel, carboplatin)
Kusaba 2007 (cisplatin, CI-5-fluorouracil)Seve 2007 (paclitaxel, cisplatin or carboplatin, etoposide)
Schneider 2007 (paclitaxel, carboplatin, capecitabine)
2008Ando 2008 (carboplatin, irinotecan)Greco 2008 (paclitaxel, carboplatin plus erlotinib, bevacizumab)
Sprenger 2008 (capecitabine, oxaliplatin)
Kim 2008 (cisplatin irinotecan)
Gross-Goupil (cisplatin, gemcitabine)
Alva 2008 (carboplatin, gemcitabine and capecitabine)
2009Yonemori 2009 (carboplatin, irinotecan)Moller 2009 (paclitaxel, cisplatin and gemcitabine)

From: Guideline chapter 5, Systemic Therapy

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.